Therapeutic targeting of the NRF2 signaling pathway in Cancer

59Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.

Abstract

Cancer is one of the most fatal diseases with an increasing incidence and mortality all over the world. Thus, there is an urgent need for novel therapies targeting major cancer-related pathways. Nuclear factor-erythroid 2-related factor 2 (NRF2) and its major negative modulator Kelch-like ECH-associated protein 1 (KEAP1) are main players of the cellular defense mechanisms against internal and external cell stressors. However, NRF2/KEAP1 signaling pathway is dysregulated in various cancers, thus promoting tumor cell survival and metastasis. In the present review, we discuss the mechanisms of normal and deregulated NRF2 signaling pathway focusing on its cancer-related functions. We further explore activators and inhibitors of this pathway as cancer targeting drug candidates in order to provide an extensive background on the subject.

Author supplied keywords

Cite

CITATION STYLE

APA

Telkoparan-Akillilar, P., Panieri, E., Cevik, D., Suzen, S., & Saso, L. (2021). Therapeutic targeting of the NRF2 signaling pathway in Cancer. Molecules, 26(5). https://doi.org/10.3390/molecules26051417

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free